After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs

Date: July 12, 2011

Location:
Dirksen Senate Office Building, Health, Education, Labor & Pensions Committee Room, SD-430
1st and C Streets, NE

Washington, DC 20510

Description:

The Pew Health Group will host a Capitol Hill forum on the release of a white paper, After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs, on Tuesday, July 12. The event is an opportunity to take an in-depth look at the risks associated with an increasingly complex, globalized and outsourced pharmaceutical supply chain and ways policy makers can make medicine supply our safer for patients.

Allan Coukell, a pharmacist and director of Medical Programs at the Pew Health Group, will moderate a panel discussion. The invited panelists are policy makers and pharmaceutical industry leaders in manufacturing and distribution:

  • Pew Representatives
    • Allan Coukell, deputy director of Medical Programs (moderator)
    • Gabey Cosel, project manager of the of the Pew Prescription Project
  • Policy makers
    • Deborah M. Autor, Esq., director, Office of Compliance, Center for Drug Evaluation and Research
  • Business Leaders
    • Heather Bresch, president, Mylan
    • John Gray, president and CEO, Healthcare Distribution Management Association (HDMA)

Time: 11:00-12:30 a.m. Doors open at 10:30 a.m.
Box lunches available immediately following the panel discussion.

Please email Yasmeen Husain at yhusain@pewtrusts.org by Monday, July 11 to RSVP.

X
(All Fields are required)